Solventum Reports Q3 2026 Results Impacted by ERP Transition and Order Reversals
Solventum (SOLV) reported third-quarter sales of $1.9 billion, a 7% decrease year-over-year primarily due to the prior year's divestiture of its Purification and Filtration business. Organic sales declined by 2.8%, heavily impacted by a $125 million reversal in advanced orders stemming from an enterprise resource planning (ERP) system transition. This timing issue negatively affected both MedSurg and Dental Solutions revenue streams. Despite these headwinds, the company demonstrated operational strength with adjusted gross margins improving to 57.1% due to programmatic savings. Management raised its full-year adjusted EPS guidance to a range of $7.20 to $7.30. Solventum continues its aggressive cost-optimization strategy, having realized $160 million in 'Transform for the Future' savings toward a $500 million annual target, while simultaneously reducing its manufacturing footprint.
Tickers: $AAPL $AMZN $DHR $GOOG $META $MSFT $NVDA $SOLV $TSLA
Topics: adjusted eps erp transition impact organic sales growth revenue decline segment performance
Read the full article at Motley Fool
Part of the story Quantum-Si Reports Q3 2026 Results Amid Transition to Proteus Platform (5 articles)